What Is LL-37?

LL-37 is a 37-amino-acid cationic peptide and the only member of the cathelicidin family identified in humans. It is derived from the C-terminal portion of hCAP18 (human cationic antimicrobial protein 18), a precursor protein stored in the secondary granules of neutrophils. The name comes from its two N-terminal leucine residues and its length. When neutrophils degranulate in response to infection or injury, protease-3 cleaves hCAP18 to release LL-37.

LL-37 is part of the innate immune system, not the adaptive one. It doesn't require prior antigen exposure to act; it is a first-responder antimicrobial that the body can deploy within minutes. It is expressed by neutrophils, natural killer cells, mast cells, and epithelial cells lining the skin, gut, and respiratory tract. Its levels in various tissues rise with infection or injury and are reduced in certain disease states — notably atopic dermatitis and cystic fibrosis — where deficient LL-37 expression contributes to heightened infection susceptibility.

In peptide communities, LL-37 is used primarily for its antimicrobial and immune-supporting properties, often by people with recurrent infections, chronic conditions with an infectious component, or an interest in augmenting innate immune defenses.

What Does the Research Say?

Evidence level: Preliminary — LL-37's antimicrobial mechanisms are thoroughly characterized in vitro and in animal models. Human data exists in disease contexts where LL-37 is deficient (atopic dermatitis, cystic fibrosis), but clinical trials for therapeutic injectable use in humans are essentially absent. The biology is well-understood; the clinical translation is not.

Mechanism

LL-37 kills pathogens through two distinct mechanisms. The first is direct membrane disruption: the peptide's cationic charge allows it to bind to negatively charged bacterial membranes, where it integrates and disrupts membrane integrity, causing cell death. This mechanism is effective against gram-positive and gram-negative bacteria, certain fungi, and some enveloped viruses. It is also active against biofilms, which are particularly difficult to treat with conventional antibiotics.

The second mechanism is immunomodulatory. LL-37 binds to and modulates toll-like receptor (TLR) signaling, both activating and dampening immune responses depending on context. It can act as a danger signal that recruits immune cells to sites of infection or injury, stimulate angiogenesis and keratinocyte migration (relevant to wound healing), and modulate inflammatory cytokine production. This dual role (antimicrobial and immunomodulatory) is unusual and is what distinguishes cathelicidins from simpler antimicrobial compounds.

The cancer relationship deserves explicit mention. LL-37 has context-dependent effects on tumor biology: it inhibits some tumors (colorectal cancer, gastric cancer) and promotes others (ovarian cancer, lung cancer). This is not a minor caveat — it reflects genuinely complex biology and is a real consideration for anyone thinking about systemic use.

Animal Studies

Animal studies on LL-37 cover wound healing, infection models, and immune regulation. Topical and injectable LL-37 has shown accelerated wound closure and improved tissue quality in rodent skin injury models. Infection models in mice have demonstrated reduced bacterial load and improved survival with LL-37 treatment, consistent with the antimicrobial mechanism.

There is also work on LL-37 in respiratory infection models, relevant to the cystic fibrosis context where patients are known to have impaired LL-37 function due to the ionic environment in CF lungs. Intranasal delivery studies in animals have shown meaningful distribution to lung tissue.

Human Studies

Human data for LL-37 exists primarily in observational and mechanistic contexts, not therapeutic trials.

The most significant human evidence comes from disease studies showing that LL-37 deficiency correlates with increased infection susceptibility. Ong et al. (2002) published a landmark study in the New England Journal of Medicine demonstrating that patients with atopic dermatitis have significantly reduced levels of LL-37 and beta-defensin-2 in skin lesions compared to psoriasis patients, explaining why atopic dermatitis patients are far more susceptible to cutaneous bacterial and viral infections. This established LL-37's role in skin defense and generated substantial interest in LL-37 augmentation as a therapeutic strategy.

In psoriasis, the picture is reversed: LL-37 levels are elevated, and LL-37 acts as a self-antigen that activates plasmacytoid dendritic cells and drives the autoimmune inflammation characteristic of the disease. LL-37 as protector in deficient states and pathogen in excess makes its biology more complicated than typical antimicrobial peptides.

No published clinical trials exist for injectable LL-37 in humans for any indication. The therapeutic development for LL-37 augmentation has been primarily in topical and inhaled formulations, not injectable, and even those programs have not advanced to Phase III.

Community and Anecdotal Reports

Community use of injectable LL-37 is limited compared to peptides like BPC-157 or Ipamorelin. Users who take it typically describe it as "immune support" — reduced frequency of infections, faster recovery when sick, or a general sense of improved immune resilience. These reports are difficult to evaluate. Immune resilience is hard to measure subjectively, and the placebo effect is substantial for anything framed as immune-supporting.

A smaller group of users with chronic infections, biofilm-related conditions, or recurrent sinusitis describe more specific reports of reduced symptoms. These are consistent with the antimicrobial mechanism in principle, though they are uncontrolled self-reports.

Common Uses

Antimicrobial Defense and Infection Resistance

The primary reason users seek LL-37. The in vitro antimicrobial data is real and extensive; whether systemic injectable LL-37 meaningfully augments antimicrobial defenses in immunocompetent humans has not been studied. The peptide is present in those tissues already — whether adding more changes the clinical picture is an open question.

Biofilm-Related Conditions

LL-37's anti-biofilm activity is a specific property that conventional antibiotics often lack. Biofilm-forming bacteria (Pseudomonas, Staphylococcus aureus, others) are notoriously antibiotic-resistant. Some users with chronic biofilm-associated conditions take LL-37 on this basis. Animal and in vitro data support the anti-biofilm mechanism; human clinical evidence for this indication is absent.

Wound Healing

LL-37 stimulates keratinocyte migration and angiogenesis, and animal wound healing data is positive. Topical formulations for wound healing have been explored. Injectable use for systemic wound support is less developed.

Immune Modulation

LL-37's TLR signaling effects give it immunomodulatory properties that interest users with autoimmune conditions, though the bidirectional nature of those effects (it can amplify or dampen immune responses depending on context) means this application requires particular caution. Using an immunomodulatory peptide with uncertain directional effects in an autoimmune context is not straightforward.

Delivery Methods

Subcutaneous Injection

Subcutaneous injection is the standard route for injectable LL-37 use in the community. The peptide is reconstituted from lyophilized powder and injected subcutaneously. Systemic bioavailability via this route has not been characterized in humans with published pharmacokinetic data.

Intranasal

Intranasal delivery is studied in the context of respiratory tract infections and cystic fibrosis-related applications, where direct delivery to the lung lining is relevant. Some community users with recurrent sinus infections use this route. No human pharmacokinetic data for intranasal LL-37 exists in published form.

PEPVi does not provide dosing guidance. Dosing decisions should be made in consultation with a qualified healthcare provider.

Safety and Side Effects

LL-37's in vitro cytotoxicity profile is the main safety concern. At concentrations substantially above physiological levels, LL-37 is cytotoxic to mammalian cells through the same membrane-disruption mechanism that kills bacteria. The therapeutic window — the range between antimicrobial effect and mammalian cell toxicity — needs careful characterization, and that characterization has not been done for injectable human use.

The cancer biology is a real consideration. LL-37 can promote tumor progression in ovarian, breast, and lung cancer contexts. Anyone with a history of these cancers, or at elevated risk, should not use systemic LL-37 without specific guidance from a physician familiar with this literature.

In autoimmune conditions where LL-37 acts as a self-antigen (psoriasis, lupus), systemic LL-37 administration could theoretically exacerbate disease. This has not been directly studied but is a plausible concern.

Community reports of side effects from injected LL-37 are: injection site reactions, transient flu-like symptoms in some users (consistent with immune activation), and occasional headache. Serious adverse events are not well-documented, but the limited scale of community use makes absence of reports insufficient reassurance.

Long-term human safety data for injectable LL-37 does not exist.

LL-37 is not FDA-approved for any therapeutic indication. It is not a scheduled controlled substance under US DEA regulations. It is sold as a research compound.

LL-37 is one of the 12 peptides targeted in the current reclassification process. For details on what changes in July 2026, see What RFK's Peptide Reclassification Means for You.

Frequently Asked Questions

Not exactly. Its antimicrobial mechanisms are real and well-documented in vitro. The value proposition against antibiotic-resistant bacteria and biofilms is scientifically interesting. But "alternative to antibiotics" would require clinical trial evidence showing it treats infections in humans — which doesn't exist for injectable use. The in vitro evidence is a starting point for drug development, not a substitute for trials.

The biology cuts both ways. In atopic dermatitis, LL-37 deficiency contributes to susceptibility to infections. In psoriasis and lupus, elevated LL-37 drives autoimmune inflammation. Using systemic LL-37 in someone with psoriasis or lupus could make things worse. The immunomodulatory effects are real but directionally unpredictable across different autoimmune contexts.

LL-37 promotes tumor progression in ovarian, lung, and breast cancer contexts through effects on tumor vascularity and cell migration. It inhibits tumor growth in colorectal and gastric contexts. This is genuine ambiguity, not alarmism — the effects depend on the tumor type and microenvironment. Anyone with a history of cancer or elevated cancer risk should discuss this specific mechanism with an oncologist before considering use.

It's the body's own antimicrobial peptide, naturally produced rather than synthetic. This is distinct from most peptides on this site, which are either synthetic or derived from foreign proteins. The natural origin also means it is a known quantity in terms of its place in immune biology, even if the consequences of exogenous supplementation at various doses are not studied.

Learn More

Sources

  1. Ong PY, Ohtake T, Brandt C, et al. "Endogenous antimicrobial peptides and skin infections in atopic dermatitis." New England Journal of Medicine, 2002. — Landmark study demonstrating LL-37 deficiency in atopic dermatitis skin lesions and its role in susceptibility to infections; established LL-37's clinical relevance in human skin defense.

  2. Zanetti M. "Cathelicidins, multifunctional peptides of the innate immunity." Journal of Leukocyte Biology, 2004. — Review of cathelicidin biology including LL-37's antimicrobial and immunomodulatory mechanisms; covers the direct membrane disruption and TLR signaling pathways.

  3. Gudmundsson GH, Agerberth B, Odeberg J, Bergman T, Olsson B, Salcedo R. "The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes." European Journal of Biochemistry, 1996. — Original characterization of LL-37's processing from hCAP18 in human neutrophils; establishes the peptide's identity and natural production pathway.